Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STARTRK-2 entrectinib basket study in NTRK, ROS1, or ALK fusion-positive solid tumors
NL-OMON60382Phase 2Completed
- Sponsor
- Roche
- Start
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of entrectinib in TRK fusion cancer (NTRK) and Nonhematologic neoplasms, sponsored by Roche. Primary endpoint: Objective Response Rate. Started Oct 2016; status: completed.
02
Drugs
entrectinib
03
Conditions
TRK fusion cancer (NTRK)Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON60382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60382.